Organic compounds -- part of the class 532-570 series – Organic compounds – Cyclopentanohydrophenanthrene ring system containing
Reexamination Certificate
2001-09-19
2003-11-25
Richter, Johann (Department: 1623)
Organic compounds -- part of the class 532-570 series
Organic compounds
Cyclopentanohydrophenanthrene ring system containing
C552S530000, C552S532000, C552S544000, C552S555000
Reexamination Certificate
active
06653491
ABSTRACT:
This application is a 371 of PCT/EP00/02323 filed Mar. 16, 2000.
The invention relates to a process for the production of 4,4-dimethyl-3&bgr;-hydroxy-pregna-8,14-diene-21-carboxylic acid esters (1) and intermediate products in the process
in which R
1
=hydrogen, branched or unbranched C
1
-C
6
alkyl, phenyl, benzyl, ortho-, meta- or para-methylphenyl, and the use for the production of 4,4-dimethyl-5&agr;-cholesta-8,14,24-trien-3&bgr;-ol (2) (FF-MAS)
Studies by Byskov et al. (Nature 1995, 374, 559) show that 4,4-dimethyl-5&agr;-cholesta-8,14,24-trien-3&bgr;-ol, formula 2, mentioned in the FF-MAS below and isolated from human follicular fluid, is an endogenous substance that regulates meiosis, to which advantageous hormonal effects are ascribed. This substance is thus important for pharmaceutical applications, for example for promoting fertility.
A first synthesis of this natural substance, which will take place in the biosynthesis of cholesterol from lanosterol, was described by Dolle et al. (J. Am. Chem. Soc. 1989, 111, 278). Starting from ergosterol, FF-MAS is obtained in an 18-stage resource-intensive synthesis sequence. Large portions of the synthesis are devoted to the chemical partial degradation of the ergosterol side chain, the subsequent creation of the FF-MAS side chain and the protective group chemistry that is necessary for achieving this goal.
A second synthesis of FF-MAS was described by Schroepfer et al., starting from dehydrocholesterol in a 13-stage synthesis (Bioorg. Med. Chem. Lett. 1997, 8, 233). Also in this synthesis, an resource-intensive protection of the diene system must be performed for the creation of a side-chain. Only four steps (epoxidation and rearrangement for protection; reduction and elimination for regeneration of the diene system) are due to the protective group strategy.
A third synthesis of FF-MAS was developed by Ruan et al. (Med. Chem. Letters 1998, 233). In this case, FF-MAS is built up starting from cholesterol in a 15-stage synthesis. Here, large portions of the synthesis are devoted to the resource-intensive build-up of the double-bond system in the steroid and the creation of the side-chain.
Additional processes are described within the still unpublished DE 198 17 520 and 198 23 677. These syntheses start from 3-oxopregn-4-ene-21-carboxylic acid esters. Central intermediate products of these processes are the 4,4-dimethyl-3&bgr;-hydroxypregna-8,14-diene-21-carboxylic acid esters that are described under general formula 1.
The object of this invention are new processes for the synthesis of these central intermediate stages. Also subjects of this invention are the new, previously unknown intermediate products that will be within the context of syntheses and can be used per se or derivatized as starting materials for the synthesis of other target molecules, for example for the synthesis of FF-MAS analogs (see WO 96/00235) and the use of compounds for the production of 4,4-dimethyl-5&agr;-cholesta-8,14,24-trien-3&bgr;-ol.
This object is achieved by the teaching of the claims.
By the process according to the invention, there will be fewer intermediate stages than in the known syntheses from the prior art, and the number of purification steps is considerably lower.
Process According to the Invention
According to Diagram 1,4,4-dimethyl-3&bgr;-hydroxypregna-8,14-diene-21-carboxylic acid esters of general formula 1 are produced in a 5-stage sequence starting from androstenedione (3).
The androstenedione that is used as starting material is commercially available.
Diagram 1
The reaction of a compound of formula 3 to form a compound of formula 4 is carried out according to processes that are known in the art (e.g., Helv. Chim. Acta 1980, 63, 1554; J. Am. Chem. Soc. 1954, 76, 2852). For example, a compound of formula 3 is reacted in the presence of bases, such as, for example, the alkali salts of lower alcohols, but preferably potassium tert-butylate with an alkylating agent, such as, for example, dimethyl sulfate, dimethyl carbonate or else methyl iodide in a solvent or solvent mixture. As solvents, lower alcohols, preferably tertiary alcohols as well as ethers, for example methyl tert-butyl ether, or tetrahydrofuran and mixtures thereof can be used. Preferred is the use of tert-butanol or a mixture that consists of tert-butanol and tetrahydrofuran. The reaction is performed in a temperature range of 0° C. to 65° C., but preferably in a temperature range of 15° C. to 50° C.
The reaction of a compound of formula 4 to form a compound of formula 5 is carried out according to processes that are known in the art (e.g., Synth. Commun. 1977, 7, 215; JOC 1988, 3947; J. Prakt. Chem. 1990, 367). For example, a compound of formula 4 is reacted in the presence of bases, such as, for example, the alkali salts of lower alcohols, but preferably sodium methylate, with a trialkylphosphonoacetate, such as, for example, triethylphosphonoacetate or trimethylphosphonoacetate in a solvent or solvent mixture. As solvents, lower, preferably primary alcohols, as well as ethers, for example methyl tert-butyl ether, or tetrahydrofuran and mixtures thereof, can be used. Preferred is the use of ethanol. The reaction is performed in a temperature range of 0° C. to 100° C., but preferably in a temperature range of 20° C. to 80° C.
Starting from a compound of formula 4, a compound of formula 5 can also be produced via condensation with Meldrum's acid or malonic acid esters, then saponification and decarboxylation and esterification.
It is familiar to one skilled in the art that R
1
can be varied in compounds of formula 5 according to standard methods. This can happen by using other alcohols in the esterification step, but also by reesterification of an already present ester. R
1
can thus have the meaning of hydrogen, methyl, ethyl, propyl, isopropyl, butyl, and the corresponding butyl isomers, pentyl and the corresponding pentyl isomers as well as hexyl and the corresponding hexyl isomers, phenyl, benzyl, ortho-, meta- and para-methylphenyl.
The reaction of a ketone of formula 5 in the corresponding 3-alcohol of formula 6 can be performed with a considerable number of reducing agents. As examples, there can be mentioned: BH
3
complexes (e.g., with tert-butylamine or trimethylamine), selectrides, sodium and lithium borohydride, inhibited lithium aluminum hydrides (e.g., LiAl(O
t
Bu)
3
H); microorganisms such as, e.g., baker's yeasts or enzymes, for example 3&bgr;-hydroxysteroid dehydrogenase, can also be used.
It is known to one skilled in the art that depending on the reagent that is used, various solvents or solvent mixtures and reaction temperatures are used. Preferred here, however, are borohydrides, such as, for example, sodium borohydride, in suitable solvents, such as, for example, lower alcohols or mixtures of alcohols with other solvents, for example dichloromethane, tetrahydrofuran or water. The reactions are performed in a temperature range of −20° C. to 40° C., but preferably in the range of −10° C. to 10° C.
The reduction of the 17-double bond in the compounds of general formula 6 is possible according to processes that are known in the art. In this case, two fundamentally different processes can be used.
In this connection, in a way that is similar to reactions that are known in the literature (Synthesis 1996, 455), a suitable reducing agent is a mixture of alkaline-earth metals in lower alcohols. For example, a compound of general formula 6 is reacted in a lower alcohol, preferably methanol, with an alkaline-earth metal, preferably magnesium. The reaction is performed in a temperature range of 0° C. to 80° C., but preferably in a temperature range of 20° C. to 50° C.
As a further reduction process, in this case the catalytic hydrogenation is presented. For example, a compound of formula 6 is hydrogenated in the presence of a suitable catalyst, such as, for example, noble metals or oxides thereof, but preferably platinum oxide. As solvents, lower alcohols, preferably ethanol, as well as ethers, for example methyl tert-butyl et
Geisler Jens
Winter Eric
Millen White Zelano & Branigan P.C.
Richter Johann
Schering AG
Zucker Paul A.
LandOfFree
Method for producing 4,4-dimethyl-3&bgr;-hydroxypregna-8,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for producing 4,4-dimethyl-3&bgr;-hydroxypregna-8,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for producing 4,4-dimethyl-3&bgr;-hydroxypregna-8,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3154776